Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Crossover Study to Evaluate the Pharmacokinetics (PK) and Safety of Two Formulations of a 7-Day Application of Memantine Transdermal Delivery System (TDS) Compared to Oral Administration of NAMENDA XR and to assess TDS adhesion in Healthy 50-80 year old Volunteers

Next Previous
X
Search
Trial Profile

A Phase 1 Crossover Study to Evaluate the Pharmacokinetics (PK) and Safety of Two Formulations of a 7-Day Application of Memantine Transdermal Delivery System (TDS) Compared to Oral Administration of NAMENDA XR and to assess TDS adhesion in Healthy 50-80 year old Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Memantine (Primary) ; Memantine
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Corium International

    • Most Recent Events

    • 21 Sep 2016 Planned number of patients changed from 36 to 48.
    • 13 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 24 Aug 2016 Summary results from this trial were used for Pre-Investigational New Drug Application (PIND) submission of once-weekly transdermal Corplex Memantine. Company received favourable written feedback from the U.S. Food and Drug Administration (FDA) on the PIND, as reported by a Corium International media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top